Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Premarin/Prempro Rxs Stabilize; Wyeth Predicts $300 Mil. Drop In 2nd Half

Executive Summary

Wyeth is seeing some stabilization in the Premarin franchise despite a 40% drop in prescriptions for Prempro and a 15% decline in Premarin scripts since release of the Women's Health Initiative study results
Advertisement

Related Content

Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments
Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments
FDA Hormone Therapy Risk Management Options Include Narrower Indication
Forest Excels: Celexa, Lexapro Help Company In Down Quarter On Wall Street
Hormone replacement therapy public meeting
Wyeth Prempro Updated Label Submission Soon; HHS To Discuss WHI Results
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Wyeth Prevnar Capacity Expansion Planned For 2003; Shortage Until Then
Advertisement
UsernamePublicRestriction

Register

PS040553

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel